Accuray, Inc. (ARAY)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$0.27+0.30%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Intact: The reason to own it still holds.
Accuray aims for about $445 million in revenue in fiscal 2026. The company repaid its 3.75% convertible notes in 2026. It is working to fix Nasdaq listing issues. These steps could stabilize the business.
Accuray is losing money and withdrew its 2026 financial guidance. Key executives left in early 2026. The stock has fallen over 40% from its high. These show ongoing problems and risk.
The market has sold off sharply, reflecting worries about losses and management issues. No clear consensus revenue or earnings growth is priced in.
Breaks if: Failure to maintain debt repayment status
Breaks if: Nasdaq delisting or failure to meet listing rules
Breaks if: Revenue falls below $440 million in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story in the healthcare sector. The company is currently loss-making but has shown strong recent financial performance, which adds complexity to its long-term thesis.
The market seems to be pricing in a high level of risk, given the company's current loss-making status and volatile management. There is also an expectation that future performance will be closely tied to broader sector trends and guidance from key players.
Management is focused on executing a transformation plan aimed at improving costs and margins, which has shown some success. However, the company faces near-term risks, including a significant probability of missing earnings expectations, which could impact sentiment.
The long-term thesis hinges on the company's ability to maintain momentum in financial performance and successfully execute its transformation plan. Additionally, external factors such as sector performance and economic conditions will play a crucial role in shaping future outcomes.
In the next 1 to 3 years, ARAY's trajectory will depend on its management execution and external market conditions. Not investment advice.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The earnings call highlighted progress in a transformation plan. This plan aims to improve cost and margin. However, revenue fell short of estimates, indicating potential challenges. The mixed quarter suggests financial pressure remains.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.